Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2525]

Study suggests adding the drug berzosertib to standard treatment for metastatic bladder cancer does not benefit patients

Study suggests adding the drug berzosertib to standard treatment for metastatic bladder cancer does not benefit...

Biomarker identified that may help predict benefits of immunotherapy

Biomarker identified that may help predict benefits of immunotherapy

FDA approves nivolumab for adjuvant treatment of urothelial carcinoma

FDA approves nivolumab for adjuvant treatment of urothelial carcinoma

One-half of patients with low-risk prostate cancer switch from active surveillance to active treatment

One-half of patients with low-risk prostate cancer switch from active surveillance to active treatment

Biomarkers of biochemical recurrence in prostate adenocarcinoma

Biomarkers of biochemical recurrence in prostate adenocarcinoma

Patients helping researchers to advance treatments for prostate cancer

Patients helping researchers to advance treatments for prostate cancer

Fear of cancer recurrence remains for certain prostate cancer survivors long after treatment

Fear of cancer recurrence remains for certain prostate cancer survivors long after treatment

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumour cells

Researchers pinpoint how PARP inhibitors combat BRCA1 and BRCA2 tumour cells

New blood test improves prostate cancer screening

New blood test improves prostate cancer screening

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status

Advanced bladder cancers respond to immunotherapy regardless of gene mutation status

More from ecancer